Studies have shown that active fund managers routinely underperform the S&P500 index*​

Kailera Therapeutics, Inc. (NASDAQ: KLRA)

KLRA Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
78.70%

KLRA Stock Analysis

KLRA PE Ratio:

KLRA PEG Ratio: Not Available

KLRA Forward EPS Growth (12 month): 0.00%

KLRA PS Ratio:

KLRA PSG Ratio: Not Available

KLRA Forward Revenue Growth (12 month): 0.00%

KLRA Articles

No data was found